Publications by authors named "B A Pons-Estel"
Association Between Antiphospholipid Antibodies and Diffuse Alveolar Hemorrhage Risk in Systemic Lupus Erythematosus: A Systematic Review and Meta-Analysis.
Rheumatology (Oxford)
November 2024
Article Synopsis
- The study investigates the link between antiphospholipid antibodies (aPL) and diffuse alveolar hemorrhage (DAH) in patients with systemic lupus erythematosus (SLE) through a systematic review and meta-analysis.
- Out of 454 studies reviewed, 9 were included, showing that SLE patients with positive aPL, especially lupus anticoagulant and anticardiolipin IgG, are more likely to experience DAH.
- Additionally, having antiphospholipid syndrome (APS) increases the risk of DAH significantly compared to patients without APS.
Article Synopsis
- The study aimed to investigate how smoking exposure is linked to organ damage in patients with systemic lupus erythematosus (SLE) using a specific damage score (SLICC-SDI) in an Argentinian cohort.
- Out of 623 SLE patients analyzed, 84% were non-smokers, while 16% were current smokers, with 17% showing severe organ damage (SLICC-SDI ≥3).
- The findings indicated that current smoking, older age, longer disease duration, and the use of cyclophosphamide are significantly associated with severe organ damage in SLE patients.
Factors predictive of severe thrombocytopenia and its impact on poor outcomes in Latin American patients with systemic lupus erythematosus: Data from a multiethnic Latin American cohort.
Semin Arthritis Rheum
December 2024
Objective: To examine the predictors of the occurrence of severe thrombocytopenia and its impact on damage accrual and mortality in SLE patients.
Methods: Factors associated with time to severe thrombocytopenia (platelet count ≤20,000/mm) occurring from the onset of SLE symptoms were assessed by Cox proportional hazards regressions. The association of severe thrombocytopenia with mortality was evaluated by logistic regression analyses while its impact on damage was by negative binomial regression.
Objectives: To identify the predictive factors of first hospitalization and associated variables to the main causes of hospitalizations in lupus patients from a Latin American cohort.
Methods: The first hospitalization after entry into the cohort during these patients' follow-up due to either lupus disease activity and/or infection was examined. Clinical and therapeutic variables were those occurring prior to the first hospitalization.
Remission and low disease activity are associated with lower healthcare costs: results from the Systemic Lupus International Collaborating Clinics (SLICC) inception cohort.
Ann Rheum Dis
September 2024
Objectives: This study aims to determine the independent impact of definitions of remission/low disease activity (LDA) on direct/indirect costs (DCs, ICs) in a multicentre inception cohort.
Methods: Patients from 31 centres in 10 countries were enrolled within 15 months of diagnosis and assessed annually. Five mutually exclusive disease activity states (DAS) were defined as (1) remission off-treatment: clinical (c) SLEDAI-2K=0, without prednisone/immunosuppressants; (2) remission on-treatment: cSLEDAI-2K=0, prednisone ≤5 mg/day and/or maintenance immunosuppressants; (3) LDA-Toronto Cohort (TC): cSLEDAI-2K≤2, without prednisone/immunosuppressants; (4) modified lupus LDA state (mLLDAS): SLEDAI-2K≤4, no activity in major organs/systems, no new activity, prednisone ≤7.